ArticleJournal of nanobiotechnology2022
Copper-based metal-organic framework impedes triple-negative breast cancer metastasis via local estrogen deprivation and platelets blockade.
Article in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 22 citations in OpenAlex.
- Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.Functional & integrative genomics · 2023Trial
- Apoptosis and cuproptosis Co-activated Copper-based metal-organic frameworks for cancer therapy.Journal of nanobiotechnology · 2024Article
- Copper in Cancer: from transition metal to potential target.Human cell · 2024Review
- Nanotechnology based gas delivery system: a "green" strategy for cancer diagnosis and treatment.Theranostics · 2024Review
- Identification of a cuproptosis-related lncRNA prognostic signature in lung adenocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- Platelet-Based Nanoparticles with Stimuli-Responsive for Anti-Tumor Therapy.International journal of nanomedicine · 2023Review
Corrections and comments
- Retraction · 2024-05-31Concerns/Issues about Image · Error in Image · Unreliable Data ·
- Retracted
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
Metastasis is one of the main causes of failure in the treatment of triple-negative breast cancer (TNBC). Abnormally estrogen level and activated platelets are the key driving forces for TNBC metastasis. Herein, an "ion/gas" bioactive nanogenerator (termed as IGBN), comprising a copper-based MOF and loaded cisplatin-arginine (Pt-Arg) prodrug is developed for metastasis-promoting tumor microenvironment reprogramming and TNBC therapy. The copper-based MOF not only serves as a drug carrier, but also specifically produces Cu
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.